CTOs on the Move

Organon

www.organon.com

 
At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day. We believe the journey to improve women`s health is critical to achieving a healthier world. We are united in our drive to better support the health of women within our company and around the globe. Together, we work toward our goal of finding solutions for the healthcare issues that matter most to ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million
  • www.organon.com
  • 30 Hudson Street
    Jersey City, NJ USA 07302
  • Phone: 551.430.6000

Executives

Name Title Contact Details
Sethu Raman
Global CISO Profile
Marcelo Canha
Profile
Sydney Powell
Associate Director, Business Technology Profile
Alex Sikorski
Associate Director of Cyber Security Technology Profile

Similar Companies

Arro Corporation

Arro Corporation is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CERTUS PHARMACEUTICALS

CERTUS PHARMACEUTICALS is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Signature Health

At Signature Health, we treat the mind and body with an integrated approach to health care. We offer mental health, primary care, and addiction recovery services.

Agrios Global Holdings

Agrios Global Holdings Ltd. operates as a holding company. The Company, through its subsidiaries, provides aeroponic equipment rental, nutrient procurement, monitoring, and agronomy consultancy services. Agrios Global Holdings serves customers in Canada.

Erytech

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.